INVIGORATE-2 Study - IV Secukinumab in Active Psoriatic Arthritis The INVIGORATE-2 trial reports that intravenous (IV) secukinumab (SEC) is both effective and safe in patients with active psoriatic arthritis (PsA), demonstrating improvements on par with subcutaneous SEC.… https://t.co/I1TVGIHByN https://t.co/WwSRQxrKAE